Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Idiopathic Thrombocytopenic Purpura (ITP)
Interventions
DRUG

IgNextGen 10%

"Ig NextGen 10% is a liquid formulation and is to be administered intravenously. At the discretion of the Investigator, patients could be administered Ig NextGen 10% in accordance with either of two dosage regimens:~Regimen One: 1 g/kg body weight of Ig NextGen 10% administered daily for two days.~Regimen Two: 0.4 g/kg body weight of Ig NextGen 10% administered daily for five days"

Trial Locations (8)

2050

Royal Prince Alfred Hospital, Sydney

2217

St George Hospital, Sydney

2605

Canberra Hospital, Canberra

3168

Monash Medical Centre, Melbourne

4102

Princess Alexandra Hospital, Brisbane

Unknown

Redcliffe Hospital, Brisbane

Royal Adelaide Hospital, Adelaide

Royal Perth Hospital, Perth

All Listed Sponsors
lead

CSL Limited

INDUSTRY

NCT00362349 - Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients | Biotech Hunter | Biotech Hunter